Skip to main content

Military Health System

Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency, U.S. Armed Forces, May 2004–Sept. 2018

Image of Staff Sgt. Cory Gage, 23d Medical Support Squadron medical laboratory technician, places a blood specimen in an automated hematology analyzer, Aug. 29, 2017, at Moody Air Force Base, Ga. Moody’s lab technicians process blood to check for a variety of cell abnormalities from infections to cancer. (U.S. Air Force photo by Airman 1st Class Erick Requadt). Staff Sgt. Cory Gage, 23d Medical Support Squadron medical laboratory technician, places a blood specimen in an automated hematology analyzer, Aug. 29, 2017, at Moody Air Force Base, Ga. Moody’s lab technicians process blood to check for a variety of cell abnormalities from infections to cancer. (U.S. Air Force photo by Airman 1st Class Erick Requadt)

Recommended Content:

Medical Surveillance Monthly Report

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic disorder most commonly associated with hemolytic anemia. Among those with G6PD deficiency, hemolytic anemia may be triggered by bacterial or viral infections and by certain foods and drugs, including the 8-aminoquinoline (8-AQ) class of antimalarials. Because 8-AQ drugs remain the only drugs approved by the U.S. Food and Drug Administration for malaria relapse prevention, the Department of Defense (DOD) requires testing of all service members' G6PD status. To estimate prevalence of G6PD deficiency among DOD service members, Composite Health Care System-generated, Health Level 7-formatted laboratory records for all service members (n=2,311,223) dated between May 2004 and Sept. 2018 were queried for G6PD testing. Corresponding demographic data were obtained from the Defense Enrollment Eligibility Reporting System. Overall prevalence of G6PD deficiency among this cohort was low, at 2.2%. Demographic trends mirrored U.S. statistics; the cohort prevalence among males (2.3%) was higher than among females (1.5%), and the prevalence among non-Hispanic blacks (9.5%) was higher than among those in any other race/ethnicity group.

What Are the New Findings?

Test results for 2,311,223 active duty service members over a 14-year period confirmed previous service-specific surveillance reports about the prevalence of G6PD deficiency. The deficiency was found in 2.2% of all service members, and the prevalence ranged from 11.2% among non-Hispanic black males to 0.3% among non-Hispanic white females. To the authors’ knowledge, this is the first DOD report widely addressing the prevalence of G6PD deficiency among active duty service members.

What Is the Impact on Readiness and Force Health Protection?

Service members who travel or deploy to malaria-endemic regions are at risk of malaria infection. Because of the risk of hemolytic anemia from use of the 8-AQ class of antimalarial drugs (e.g., primaquine, tafenoquine), military leaders should be aware of G6PD deficiency diagnoses among service members under their purview and should continue adherence to current DOD G6PD screening policies.

Background

Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme for the pentose phosphate pathway in the erythrocyte because it converts glucose-6-phosphate to 6-phosphoglucono-d-lactone. G6PD also converts nicotinamide adenine dinucleotide phosphate (NADP) to the reduced form of NADP (NADPH), a critical redox-active cofactor that mitigates oxidative damage to the erythrocytes.G6PD deficiency is a genetic condition arising from mutations on the Gd gene on the X chromosome that encodes G6PD enzyme. As an X-linked recessive genetic disorder, G6PD deficiency has a higher prevalence in males than females.1 Reduced G6PD activity in G6PD deficient individuals can cause hemolysis with different manifestations (e.g., kernicterus in infants and hemolytic crises) from exposures to oxidative stressors including certain medications, fava beans, and infections.1,2 For example, members of the 8-aminoquinoline (8-AQ) class of antimalarial drugs can cause hemolysis in the G6PD deficient population. 

8-AQ class antimalarial drugs (primaquine and the newly Food and Drug Administration (FDA)-approved tafenoquine for weekly chemoprophylaxis and single-dose radical cure) are important because they target hypnozoites—a dormant form of the malaria parasite common in Plasmodium vivax and P. ovale infections that can emerge from the liver and cause relapse days to years after treatment has cleared the malaria parasites from the circulating red blood cells. Although these infections are less often fatal than P. falciparum infections, they still can cause significant morbidity because of relapse from the dormant form of the parasites. Because the 8-AQ class drugs are the only FDA-approved drugs for malaria relapse prevention, the Department of Defense (DOD) mandated G6PD testing of service members at the time of military accession as early as 1981 (Instruction 6465.13,4 updated with DOD Instruction 6465.015 in 2015 and 6025.146 in 2018), and the Army implemented additional G6PD screening of soldiers deploying to malaria endemic regions as early as 2004.7 However, given that this drug class may trigger hemolytic anemia among those who are G6PD deficient, it is important to adhere to DOD G6PD screening instructions and provide results to command leaders and tested individuals for situational awareness and force protection.

Thus, the objectives of this surveillance report are to describe the prevalence of G6PD deficiency among active duty DOD service members who were screened during 2004–2018 and remind the DOD medical community to consider the risk of hemolytic anemia when prescribing the use of the 8-AQ class of antimalarial drugs.

Methods

This cross-sectional study used Composite Health Care System-generated, Health Level 7-formatted chemistry laboratory records from 01 May 2004 through 30 Sept. 2018 and queried for G6PD laboratory test results among all active duty, recruit, and active reserve DOD service members tested at fixed military treatment facilities (MTFs). Generally, G6PD testing occurs during accession (recruit training), which is reflected in over 90% of these records.

Key terms used to identify G6PD assays were "G6" or "glucose 6" in the test ordered or test name fields. G6PD tests are often run in panels with other genetic and hemoglobin tests. Records were excluded from the analysis if the test name field contained text indicating other genetic testing (e.g., "sickle cell anemia"), "red blood count", "hemoglobin testing", "miscellaneous". or if the test type could not be determined.

G6PD laboratory test result fields were alpha character–based or numeric. Character-based records with a test result of "Not Deficient", "High" or "Normal" were classified as "Not Deficient", Records with a test result of "Deficient" or "Low" were classified as "Deficient". Because of laboratory testing variations between MTFs, numeric test results were classified based upon the reference ranges indicated in the record. If a record had no reference range but units of measure were noted, the reference range was inferred based on other tests with the same unit of measure. In an effort to provide an accurate denominator, if the test result was numeric and the units of measure and the reference ranges could not be extrapolated from the data, the record result was classified as "Unknown." To avoid misclassification of results, if the test result field referred to the free-text result notes field, the record was classified as "Unknown".

If a service member had more than 1 record and the test results differed, the records were prioritized as follows: a "Deficient" record was retained over a "Not Deficient" or "Unknown" record, and a "Not Deficient" record was retained over an "Unknown" record. Only 1 record per service member was retained for analysis.

Final records were matched to the most recent Defense Enrollment Eligibility Reporting System (DEERS) record for each service member to obtain race/ethnicity and service affiliation. Records were not included in the final dataset if there were no matching DEERS records (n=29,642). Demographic frequencies and distributions for the final cohort were calculated using SAS software, version 9.4 (SAS Institute, Cary, NC).

Results

Overall results are presented in Table 1. G6PD laboratory test results for 2,311,223 service members were evaluated. Examination of laboratory records indicated that the vast majority (97.7%) of service members tested were not G6PD deficient. Only 0.13% of all records could not be classified. The majority of service members represented in this analysis (89.5%) had 1 record for G6PD testing, 8.7% had 2 records, and the remaining 1.8% had 3 or more records (data not shown). Of those with more than 1 record where the classification changed, the following changes were observed: “Not Deficient” to “Deficient” (4.6%), “Unknown” to “Deficient” (3.7%), and “Unknown” to “Not Deficient” (91.7%) (data not shown).

Of the 2,311,223 service members identified in the laboratory records as having been tested, 83.3% were male and 16.7% were female. Sex was not indicated in 3,070 records (0.13%). Males were more likely to be classified as G6PD deficient (2.3%) than females (1.5%).

Race/ethnicity was classified as “other/unknown” in 3.0% of all records (Table 1). Non-Hispanic blacks were most likely to be classified as G6PD deficient (9.5%), followed by Asians/Pacific Islanders (2.9%) and Hispanics (1.5%). Non-Hispanic whites were the least likely to be classified as G6PD deficient (0.4%).

The G6PD classifications stratified by race/ethnicity and sex are shown in Table 2. Among males, non-Hispanic black service members were the most likely to be classified as G6PD deficient (11.2%), followed by Asian/Pacific Islander and Hispanic service members (3.3% and 1.7%, respectively). Non-Hispanic black males were more than twice as likely as non-Hispanic black females (4.7%) to be classified as G6PD deficient. Non-Hispanic black females had the highest proportion of G6PD deficiency of all female race/ethnicity groups. Although the non-Hispanic white race/ethnicity group represented the largest proportion of service members tested (59.8%), males and females in this race/ethnicity group were least likely to be G6PD deficient (0.4% and 0.3%, respectively).

Table 3 illustrates the G6PD results by service. The proportions of service members who tested positive for G6PD deficiency were broadly similar among the services. The Army had the highest percentage of service members with G6PD deficiency (2.7%), followed by the Air Force (2.3%) and Navy (2.2%). The Coast Guard (1.2%) and the Marine Corps (1.1%) had the lowest rates of service members with G6PD deficiency.

Editorial Comment

The current study found an overall G6PD deficiency prevalence rate of 2.2% (n=49,897) among the 2,311,223 active and reserve component service members with laboratory results. To the authors’ knowledge, this is the largest study of G6PD deficiency screening among DOD service members. The results of the current analysis are consistent with other studies that have found that non-Hispanic black males are more likely to be G6PD deficient than any other race/ethnicity group.7–10

Before adoption of the newly FDA-approved tafenoquine as the primary force health protection measure for DOD service members against malaria infection, it is critical to understand the indications for prevention and treatment as well as the limitations.11 Regardless of an improved drug performance, including a radical curative efficacy, longer drug half-life, and once-weekly dosing regimen, tafenoquine still retains the risk of inducing hemolytic anemia in G6PD deficient individuals.

The results of this study must be interpreted within the context of several limitations. Laboratory records queried for this analysis were derived from fixed MTFs and do not include records from in-theater, shipboard, battalion aid station, or Purchased CareThe TRICARE Health Program is often referred to as purchased care. It is the services we “purchase” through the managed care support contracts.purchased care providers, although inclusion of these records, were they available, would not be expected to alter the findings presented herein. Genetic testing is generally performed during the accession phase of military service, so very few tests would need to be performed at austere or remote locations. Although validation steps were taken to avoid misclassification, it is possible that some results were misclassified. Because less than 1.0% of all records were classified as "Unknown", it is unlikely that these results would change the overall prevalence rates. Final laboratory records were matched to the most recent DEERS record for each service member; a service member may have changed service affiliation after the laboratory testing, but this practice is uncommon. Additionally, laboratory data were derived from DOD service members and may not be generalizable to a larger U.S. civilian population.

Given the findings of the current analysis, DOD health are providers, Combatant Commanders, and their command surgeons in areas of responsibility that include malaria-endemic regions should remain aware of the risks of 8-AQ hemolytic anemia in G6PD deficient service members. In addition, targeted health education and risk management instruction should be provided to G6PD deficient service members in order to mitigate adverse health outcomes. Furthermore, continued implementation of the DOD's G6PD screening instruction is required to mitigate G6PD deficiency-associated adverse events.

Author affiliations: Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, MD (MAJ Jangwoo Lee); Defense Health Agency, Combat Support, Health Care Operations, Public Health Division, Armed Forces Health Surveillance Branch, Navy Satellite (Beth T. Poitras)

Acknowledgments: The authors thank LTC Chad C. Black, LTC Mara Kreishman-Deitrick, COL James E. Moon, COL Viseth Ngauy, MAJ Brandon S. Pybus, and Angela D. Schlein for their support of this analysis and report.

Disclaimer: The views expressed in this report are those of the authors and do not necessarily reflect the official policy or position of the Armed Forces Health Surveillance Branch, the Defense Health Agency, the Department of the Army, the Department of the Navy, the Department of Defense, or the U.S. Government. Analytic support was provided by the Armed Forces Health Surveillance Branch of the Public Health Division at the Defense Health Agency. Authors are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties.

References

  1. Richardson SR, O'Malley GF. (2019). Glucose 6 phosphate dehydrogenase (G6PD) deficiency. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470315/. Accessed 23 Jan. 2019.
  2. Luzzatto L, Arese P. Favism and glucose-6-phosphate dehydrogenase deficiency. N Eng J Med. 2018;378(1):60–71.
  3. Department of Defense Instruction 6465.1. Hemoglobin S and erythrocyte glucose-6-phosphate dehydrogenase deficiency test program. 29 July 1981.
  4. Webber BJ, Witkop CT. Screening for sickle-cell trait at accession to the United States military. Mil Med. 2014;179(11):1184–1189.
  5. Department of Defense Instruction 6465.01. Erythrocyte glucose-6-phosphate dehydrogenase deficiency (G6PD) and sickle cell trait screening programs. 17 July 2015.
  6. Department of Defense Instruction 6025.14. Active duty service members (ADSM) erythrocyte glucose-6-phosphate dehydrogenase (G6PD) deficiency and sickle cell trait (SCT) screening. 6 Dec. 2018.
  7. Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duelm F, Hospenthal DR. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. Mil Med. 2006;171(9):905–907.
  8. Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Eng J Med. 1979;300(18):1001–5.
  9. Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med. 1962;109:209–234.
  10. Uddin DE, Dickson LG, Brodine CE. Glucose-6-phosphate dehydrogenase deficiency in military recruits. JAMA. 1974;227(12):1408–1409.
  11. Fukuda M, Wojnarski M, Martin N, Zottig V, Waters NC. Editorial: Malaria in the Korean Peninsula: risk factors, latent infections, and the possible role of tafenoquine, a new antimalarial weapon. MSMR. 2018;25(11):2–3.

Results of G6PD deficiency laboratory testing among active duty DOD service members, 2004–2018

Classification of G6PD laboratory records among active duty DOD service members, by race/ethnicity and sex, 2004–2018

Classification of G6PD laboratory records among active duty DOD service members, by service, 2004–2018

You also may be interested in...

MSMR Vol. 29 No. 09 - September 2022

Report
9/1/2022

A monthly publication of the Armed Forces Health Surveillance Division. This issue of the peer-reviewed journal contains the following articles: Surveillance trends for SARS-CoV-2 and other respiratory pathogens among U.S. Military Health System Beneficiaries, Sept. 27, 2020 – Oct. 2,2021; Establishment of SARS-CoV-2 genomic surveillance within the MHS during March 1 – Dec. 31 2020; Suicide behavior among heterosexual, lesbian/gay, and bisexual active component service members in the U.S. Armed Forces; Brief report: Phase I results using the Virtual Pooled Registry Cancer Linkage system (VPR-CLS) for military cancer surveillance.

Recommended Content:

Health Readiness & Combat Support | Public Health | Medical Surveillance Monthly Report

MSMR Vol. 29 No. 08 - August 2022

Report
8/1/2022

A monthly publication of the Armed Forces Health Surveillance Division. This issue of the peer-reviewed journal contains the following articles: Surveillance trends for SARS-CoV-2 and other respiratory pathogens among U.S. Military Health System Beneficiaries, Sept. 27, 2020 – Oct. 2,2021; Establishment of SARS-CoV-2 genomic surveillance within the MHS during March 1 – Dec. 31 2020; Suicide behavior among heterosexual, lesbian/gay, and bisexual active component service members in the U.S. Armed Forces; Brief report: Phase I results using the Virtual Pooled Registry Cancer Linkage system (VPR-CLS) for military cancer surveillance.

Recommended Content:

Medical Surveillance Monthly Report

Musculoskeletal Injuries During U.S. Air Force Special Warfare Training Assessment and Selection, Fiscal Years 2019–2021.

Article
8/1/2022
U.S. Air Force Capt. Hopkins, 351st Special Warfare Training Squadron, Instructor Flight commander and Chief Combat Rescue Officer (CRO) instructor, conducts a military free fall equipment jump from a DHC-4 Caribou aircraft in Coolidge, Arizona, July 17, 2021. Hopkins is recognized as the 2020 USAF Special Warfare Instructor Company Grade Officer of the Year for his outstanding achievement from January 1 to December 31, 2020.

Musculoskeletal (MSK) injuries are costly and the leading cause of medical visits and disability in the U.S. military.1,2 Within training envi­ronments, MSK injuries may lead to a loss of training, deferment to a future class, or voluntary disenrollment from a training pipeline, all of which are impediments to maintaining full levels of manpower and resources for the Department of Defense.

Recommended Content:

Medical Surveillance Monthly Report

Brief Report: Pain and Post-Traumatic Stress Disorder Screening Outcomes Among Military Personnel Injured During Combat Deployment.

Article
8/1/2022
U.S. Air Force Airman 1st Class Miranda Lugo, right, 18th Operational Medical Readiness Squadron mental health technician and Guardian Wingman trainer, and Maj. Joanna Ho, left, 18th OMRS director of psychological health, discuss the suicide prevention training program, Guardian Wingman, at Kadena Air Base, Japan, Aug. 20, 2021. Guardian Wingman aims to promote wingman culture and early help-seeking behavior. (U.S. Air Force photo by Airman 1st Class Anna Nolte)

The post-9/11 U.S. military conflicts in Iraq and Afghanistan lasted over a decade and yielded the most combat casualties since the Vietnam War. While patient survivability increased to the high­est level in history, a changing epidemiology of combat injuries emerged whereby focus shifted to addressing an array of long-term sequelae, including physical, psychologi­cal, and neurological issues.

Recommended Content:

Medical Surveillance Monthly Report

Prevalence and Distribution of Refractive Errors Among Members of the U.S. Armed Forces and the U.S. Coast Guard, 2019.

Article
8/1/2022
Ophthamologist Air Force Maj. Thuy Tran evaluates a patient during an eye exam. (U.S. Air Force photo by Tech. Sgt. John Hughel)

During calendar year 2019, the estimated prevalence of myopia, hyperopia, and astigmatism were 17.5%, 2.1%, and 11.2% in the active component of the U.S. Armed Forces and 10.1%, 1.2%, and 6.1% of the U.S. Coast Guard, respectively.

Recommended Content:

Medical Surveillance Monthly Report

MSMR Vol. 29 No. 07 - July 2022

Report
7/1/2022

A monthly publication of the Armed Forces Health Surveillance Division. This issue of the peer-reviewed journal contains the following articles: Surveillance trends for SARS-CoV-2 and other respiratory pathogens among U.S. Military Health System Beneficiaries, Sept. 27, 2020 – Oct. 2,2021; Establishment of SARS-CoV-2 genomic surveillance within the MHS during March 1 – Dec. 31 2020; Suicide behavior among heterosexual, lesbian/gay, and bisexual active component service members in the U.S. Armed Forces; Brief report: Phase I results using the Virtual Pooled Registry Cancer Linkage system (VPR-CLS) for military cancer surveillance.

Recommended Content:

Health Readiness & Combat Support | Public Health | Medical Surveillance Monthly Report

Establishment of SARS-CoV-2 Genomic Surveillance Within the Military Health System During 1 March–31 December 2020.

Article
7/1/2022
Dr. Peter Larson loads an Oxford Nanopore MinION sequencer in support of COVID-19 sequencing assay development at the U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland. (Photo by John Braun Jr., USAMRIID.)

This report describes SARS-CoV-2 genomic surveillance conducted by the Department of Defense (DOD) Global Emerging Infections Surveillance Branch and the Next-Generation Sequencing and Bioinformatics Consortium (NGSBC) in response to the COVID-19 pandemic. Samples and sequence data were from SARS-CoV-2 infections occurring among Military Health System (MHS) beneficiaries from 1 March to 31 December 2020.

Recommended Content:

Medical Surveillance Monthly Report

Surveillance Trends for SARS-CoV-2 and Other Respiratory Pathogens Among U.S. Military Health System Beneficiaries, 27 September 2020–2 October 2021.

Article
7/1/2022
Staff Sgt. Misty Poitra and Senior Airman Chris Cornette, 119th Medical Group, collect throat swabs during voluntary COVID-19 rapid drive-thru testing for members of the community while North Dakota Army National Guard Soldiers gather test-subject data in the parking lot of the FargoDome in Fargo, N.D., May 3, 2020. The guardsmen partnered with the N.D. Department of Health and other civilian agencies in the mass-testing efforts of community volunteers. (U.S. Air National Guard photo by Chief Master Sgt. David H. Lipp)

Respiratory pathogens, such as influenza and adenovirus, have been the main focus of the Department of Defense Global Respiratory Pathogen Surveillance Program (DoDGRPSP) since 1976.1. However, DoDGRPSP also began focusing on SARS-CoV-2 when COVID-19 was declared a pandemic illness in early March 2020.2. Following this declaration, the DOD quickly adapted and organized its respiratory surveillance program, housed at the U.S. Air Force School of Aerospace Medicine (USAFSAM), in response to this emergent virus.

Recommended Content:

Medical Surveillance Monthly Report

Suicide Behavior Among Heterosexual, Lesbian/Gay, and Bisexual Active Component Service Members in the U.S. Armed Forces.

Article
7/1/2022
  The DOD’s theme for National Suicide Prevention Month is “Connect to Protect: Support is Within Reach.” Deployments, COVID-19 restrictions, and the upcoming winter season are all stressors and potential causes for depression that could lead to suicidal ideations. Options are available to individuals who are having thoughts of suicide and those around them (Photo by Kirk Frady, Regional Health Command Europe).

Lesbian, gay, and bisexual (LGB) individuals are at a particularly high risk for suicidal behavior in the general population of the United States. This study aims to determine if there are differences in the frequency of lifetime suicide ideation and suicide attempts between heterosexual, lesbian/gay, and bisexual service members in the active component of the U.S. Armed Forces. Self-reported data from the 2015 Department of Defense Health-Related Behaviors Survey were used in the analysis.

Recommended Content:

Medical Surveillance Monthly Report

Brief Report: Phase I Results Using the Virtual Pooled Registry Cancer Linkage System (VPR-CLS) for Military Cancer Surveillance.

Article
7/1/2022
A patient at Naval Hospital Pensacola prepares to have a low-dose computed tomography test done to screen for lung cancer. Lung cancer is the leading cause of cancer-related deaths among men and women. Early detection can lower the risk of dying from this disease. (U.S. Navy photo by Jason Bortz)

The Armed Forces Health Surveillance Division, as part of its surveillance mission, periodically conducts studies of cancer incidence among U.S. military service members. However, service members are likely lost to follow-up from the Department of Defense cancer registry and Military Health System data sets after leaving service and during periods of time not on active duty.

Recommended Content:

Medical Surveillance Monthly Report

Morbidity Burdens Attributable to Various Illnesses and Injuries, Deployed Active and Reserve Component Service Members, U.S. Armed Forces, 2021

Article
6/1/2022
Morbidity Burdens Attributable to Various Illnesses and Injuries, Deployed Active and Reserve Component Service Members, U.S. Armed Forces, 2021

As in previous years, among service members deployed during 2021, injury/poisoning, musculoskeletal diseases and signs/symptoms accounted for more than half of the total health care burden during deployment. Compared to garrison disease burden, deployed service members had relatively higher proportions of encounters for respiratory infections, skin diseases, and infectious and parasitic diseases. The recent marked increase in the percentage of total medical encounters attributable to the ICD diagnostic category "other" (23.0% in 2017 to 44.4% in 2021) is likely due to increases in diagnostic testing and immunization associated with the response to the COVID-19 pandemic.

Recommended Content:

Medical Surveillance Monthly Report

Hospitalizations, Active Component, U.S. Armed Forces, 2021

Article
6/1/2022
Hospitalizations, Active Component, U.S. Armed Forces, 2021

The hospitalization rate in 2021 was 48.0 per 1,000 person-years (p-yrs), the second lowest rate of the most recent 10 years. For hospitalizations limited to military facilities, the rate in 2021 was the lowest for the entire period. As in prior years, the majority (71.2%) of hospitalizations were associated with diagnoses in the categories of mental health disorders, pregnancy-related conditions, injury/poisoning, and digestive system disorders.

Recommended Content:

Medical Surveillance Monthly Report

Surveillance snapshot: Illness and injury burdens, reserve component, U.S. Armed Forces, 2021

Article
6/1/2022
Surveillance snapshot: Illness and injury burdens, reserve component, U.S. Armed Forces, 2021

Recommended Content:

Medical Surveillance Monthly Report

Absolute and Relative Morbidity Burdens Attributable to Various Illnesses and Injuries, Active Component, U.S. Armed Forces, 2021

Article
6/1/2022
Absolute and Relative Morbidity Burdens Attributable to Various Illnesses and Injuries, Active Component, U.S. Armed Forces, 2021

In 2021, as in prior years, the medical conditions associated with the most medical encounters, the largest number of affected service members, and the greatest number of hospital days were in the major categories of injuries, musculoskeletal disorders, and mental health disorders. Despite the pandemic, COVID-19 accounted for less than 2% of total medical encounters and bed days in active component service members.

Recommended Content:

Medical Surveillance Monthly Report

Absolute and Relative Morbidity Burdens Attributable to Various Illnesses and Injuries, Non-service Member Beneficiaries of the Military Health System, 2021

Article
6/1/2022
Absolute and Relative Morbidity Burdens Attributable to Various Illnesses and Injuries, Non-service Member Beneficiaries of the Military Health System, 2021

In 2021, mental health disorders accounted for the largest proportions of the morbidity and health care burdens that affected the pediatric and younger adult beneficiary age groups. Among adults aged 45–64 and those aged 65 or older, musculoskeletal diseases accounted for the most morbidity and health care burdens. As in previous years, this report documents a substantial majority of non-service member beneficiaries received care for current illness and injury from the Military Health System as outsourced services at non-military medical facilities.

Recommended Content:

Medical Surveillance Monthly Report
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 13
Refine your search
Last Updated: October 26, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery